Acute myeloid leukemia has a certain mortality rate. Acute myeloid leukemia is a malignant clonal disease originating from bone marrow hematopoietic stem cells and is characterized by a very acute onset and very rapid progression, with significant anemia, or thrombocytopenia, within a short period of time. As a result, early patients can die from severe infections or bleeding, and the vast majority of patients will die within 3-6 months (the natural course of the disease) if treatment is not provided promptly. Once acute myeloid leukemia is diagnosed, aggressive combination chemotherapy needs to be given. Chemotherapy itself carries certain risks, with a chemotherapy-related mortality rate of about 5% and a remission rate of more than 70%. Once in remission, follow-up consolidation therapy is needed to prolong the patient’s survival.